Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin alfa + fructose + tetracycline hydrochloride + cetrorelix acetate
- Development stage
- Unknown
- Lead developer
- EMD Serono
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Administration
- Subcutaneous, Topical
01
Overview
This combination represents a clinical protocol used in assisted reproductive technology (ART), specifically for in vitro fertilization and embryo transfer (IVF-ET) in patients with decreased ovarian reserve (DOR). It consists of **follitropin alfa** (a recombinant follicle-stimulating hormone used for controlled ovarian stimulation), **cetrorelix acetate** (a GnRH antagonist used to prevent premature ovulation), and a vaginal preparation containing **tetracycline hydrochloride** and **fructose** (used for local disinfection and maintaining the vaginal environment prior to procedures). This specific regimen is being evaluated by the Peking University Third Hospital in Phase 3 trials to determine the efficacy of adding sequential traditional Chinese medicine (TCM) formulas to standard IVF-ET protocols to improve pregnancy outcomes. The protocol aims to optimize follicular development and endometrial receptivity while minimizing the risk of infection and premature luteinization.
- Other names
- follitropin alfa + fructose + tetyacycline hydrochloride + cetrorelix acetate
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)Bacterial RibosomeFSHR (Follicle-stimulating hormone receptor)
Beyond the preview
Go deeper on follitropin alfa + fructose + tetracycline hydrochloride + cetrorelix acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin alfa + fructose + tetracycline hydrochloride + cetrorelix acetate.